Skip to main content
Top
Published in: Supportive Care in Cancer 5/2018

01-05-2018 | Original Article

Evaluation of a specialized oncology nursing supportive care intervention in newly diagnosed breast and colorectal cancer patients following surgery: a cluster randomized trial

Authors: Jonathan Sussman, Daryl Bainbridge, Timothy J. Whelan, Kevin Brazil, Sameer Parpia, Jennifer Wiernikowski, Susan Schiff, Gary Rodin, Myles Sergeant, Doris Howell

Published in: Supportive Care in Cancer | Issue 5/2018

Login to get access

Abstract

Background

Better coordination of supportive services during the early phases of cancer care has been proposed to improve the care experience of patients. We conducted a randomized trial to test a community-based nurse-led coordination of care intervention in cancer patients.

Methods

Surgical practices were cluster randomized to a control group involving usual care practices or a standardized nursing intervention consisting of an in-person supportive care assessment with ongoing support to meet identified needs, including linkage to community services. Newly diagnosed breast and colorectal cancer patients within 7 days of cancer surgery were eligible. The primary outcome was the patient-reported outcome (PRO) of continuity of care (CCCQ) measured at 3 weeks. Secondary outcomes included unmet supportive care needs (SCNS), quality of life (EORTC QLQ-C30), health resource utilization, and level of uncertainty with care trajectory (MUIS) at 3 and/or 8 weeks.

Results

A total of 121 breast and 72 colorectal patients were randomized through 28 surgical practices. There was a small improvement in the informational domain of continuity of care (difference 0.29 p = 0.05) and a trend to less emergency room use (15.8 vs 7.1%) (p = 0.07). There were no significant differences between groups on unmet need, quality of life, or uncertainty.

Conclusion

We did not find substantial gaps in the PROs measured immediately following surgery for breast and colorectal cancer patients. The results of this study support a more targeted approach based on need and inform future research focused on improving navigation during the initial phases of cancer treatment.
ClinicalTrials.​gov Identifier: NCT00182234.
SONICS—Effectiveness of Specialist Oncology Nursing.
Appendix
Available only for authorised users
Literature
7.
go back to reference Institute of Medicine and National Research Council of the National Academies. From cancer patient to cancer survivor: lost in transition (2005) Washington. The National Academies Press, D.C. Institute of Medicine and National Research Council of the National Academies. From cancer patient to cancer survivor: lost in transition (2005) Washington. The National Academies Press, D.C.
12.
go back to reference Fitch M (2000) Supportive care for cancer patients. Hosp Q 3(4):39–46PubMed Fitch M (2000) Supportive care for cancer patients. Hosp Q 3(4):39–46PubMed
13.
go back to reference Institute of Medicine of the National Academies. Cancer care for the whole patient: meeting psychosocial health needs (2008) Washington. The National Academies Press, D.C. Institute of Medicine of the National Academies. Cancer care for the whole patient: meeting psychosocial health needs (2008) Washington. The National Academies Press, D.C.
20.
go back to reference Flocke SA (1997) Measuring attributes of primary care: development of a new instrument. J Fam Pract 45(1):64–74PubMed Flocke SA (1997) Measuring attributes of primary care: development of a new instrument. J Fam Pract 45(1):64–74PubMed
23.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://doi.org/10.1093/jnci/85.5.365 CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://​doi.​org/​10.​1093/​jnci/​85.​5.​365 CrossRefPubMed
24.
go back to reference Mishel MH (1999) Uncertainty in chronic illness. Annu Rev Nurs Res 17:269–294PubMed Mishel MH (1999) Uncertainty in chronic illness. Annu Rev Nurs Res 17:269–294PubMed
39.
go back to reference Marcon A, Bravi F, Foglino S, Angelastro A, Carretta E, Altini MP, Fantini MP, Carradori T (2014) Continuity of care of cancer patients. Analysis of theoretical models and survey tools of continuity of care in people with a cancer diagnosis. Ann Ig 26(4):380–390PubMed Marcon A, Bravi F, Foglino S, Angelastro A, Carretta E, Altini MP, Fantini MP, Carradori T (2014) Continuity of care of cancer patients. Analysis of theoretical models and survey tools of continuity of care in people with a cancer diagnosis. Ann Ig 26(4):380–390PubMed
Metadata
Title
Evaluation of a specialized oncology nursing supportive care intervention in newly diagnosed breast and colorectal cancer patients following surgery: a cluster randomized trial
Authors
Jonathan Sussman
Daryl Bainbridge
Timothy J. Whelan
Kevin Brazil
Sameer Parpia
Jennifer Wiernikowski
Susan Schiff
Gary Rodin
Myles Sergeant
Doris Howell
Publication date
01-05-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 5/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3981-4

Other articles of this Issue 5/2018

Supportive Care in Cancer 5/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine